nodes	percent_of_prediction	percent_of_DWPC	metapath
Tasosartan—AGTR2—Peptide ligand-binding receptors—KISS1—head and neck cancer	0.0746	0.0746	CbGpPWpGaD
Tasosartan—AGTR2—Peptide ligand-binding receptors—GRP—head and neck cancer	0.0615	0.0615	CbGpPWpGaD
Tasosartan—AGTR2—Class A/1 (Rhodopsin-like receptors)—KISS1—head and neck cancer	0.0501	0.0501	CbGpPWpGaD
Tasosartan—AGTR2—Class A/1 (Rhodopsin-like receptors)—GRP—head and neck cancer	0.0412	0.0412	CbGpPWpGaD
Tasosartan—AGTR2—GPCR ligand binding—KISS1—head and neck cancer	0.0381	0.0381	CbGpPWpGaD
Tasosartan—AGTR2—GPCR ligand binding—GRP—head and neck cancer	0.0314	0.0314	CbGpPWpGaD
Tasosartan—CYP3A4—Aflatoxin B1 metabolism—GSTM1—head and neck cancer	0.0259	0.0259	CbGpPWpGaD
Tasosartan—AGTR1—G alpha (q) signalling events—KISS1—head and neck cancer	0.0246	0.0246	CbGpPWpGaD
Tasosartan—AGTR1—Peptide ligand-binding receptors—KISS1—head and neck cancer	0.0243	0.0243	CbGpPWpGaD
Tasosartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—KISS1—head and neck cancer	0.022	0.022	CbGpPWpGaD
Tasosartan—AGTR2—GPCR downstream signaling—KISS1—head and neck cancer	0.0215	0.0215	CbGpPWpGaD
Tasosartan—AGTR1—Arf6 trafficking events—CDH1—head and neck cancer	0.0213	0.0213	CbGpPWpGaD
Tasosartan—AGTR1—G alpha (q) signalling events—GRP—head and neck cancer	0.0203	0.0203	CbGpPWpGaD
Tasosartan—CYP3A4—Benzo(a)pyrene metabolism—CYP1A1—head and neck cancer	0.0201	0.0201	CbGpPWpGaD
Tasosartan—AGTR1—Peptide ligand-binding receptors—GRP—head and neck cancer	0.02	0.02	CbGpPWpGaD
Tasosartan—AGTR2—Signaling by GPCR—KISS1—head and neck cancer	0.0196	0.0196	CbGpPWpGaD
Tasosartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—GRP—head and neck cancer	0.0181	0.0181	CbGpPWpGaD
Tasosartan—AGTR2—GPCR downstream signaling—GRP—head and neck cancer	0.0177	0.0177	CbGpPWpGaD
Tasosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—KISS1—head and neck cancer	0.0163	0.0163	CbGpPWpGaD
Tasosartan—AGTR2—Signaling by GPCR—GRP—head and neck cancer	0.0161	0.0161	CbGpPWpGaD
Tasosartan—AGTR1—Arf6 signaling events—EGFR—head and neck cancer	0.0158	0.0158	CbGpPWpGaD
Tasosartan—AGTR1—Allograft Rejection—CASP8—head and neck cancer	0.0143	0.0143	CbGpPWpGaD
Tasosartan—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—RARB—head and neck cancer	0.0135	0.0135	CbGpPWpGaD
Tasosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—GRP—head and neck cancer	0.0134	0.0134	CbGpPWpGaD
Tasosartan—CYP3A4—Fatty Acid Omega Oxidation—CYP1A1—head and neck cancer	0.0127	0.0127	CbGpPWpGaD
Tasosartan—AGTR1—Angiopoietin receptor Tie2-mediated signaling—MAPK3—head and neck cancer	0.0125	0.0125	CbGpPWpGaD
Tasosartan—AGTR1—GPCR ligand binding—KISS1—head and neck cancer	0.0124	0.0124	CbGpPWpGaD
Tasosartan—CYP3A4—Estrogen metabolism—GSTM1—head and neck cancer	0.0122	0.0122	CbGpPWpGaD
Tasosartan—AGTR1—Angiopoietin receptor Tie2-mediated signaling—MAPK1—head and neck cancer	0.0119	0.0119	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—KISS1—head and neck cancer	0.0116	0.0116	CbGpPWpGaD
Tasosartan—CYP3A4—Estrogen metabolism—CYP1A1—head and neck cancer	0.0115	0.0115	CbGpPWpGaD
Tasosartan—AGTR1—Allograft Rejection—IL2—head and neck cancer	0.0108	0.0108	CbGpPWpGaD
Tasosartan—CYP3A4—Xenobiotics—CYP1A1—head and neck cancer	0.0106	0.0106	CbGpPWpGaD
Tasosartan—AGTR1—Angiopoietin receptor Tie2-mediated signaling—PIK3CA—head and neck cancer	0.0103	0.0103	CbGpPWpGaD
Tasosartan—AGTR1—GPCR ligand binding—GRP—head and neck cancer	0.0102	0.0102	CbGpPWpGaD
Tasosartan—CYP3A4—Tamoxifen metabolism—CYP1A1—head and neck cancer	0.0102	0.0102	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—GRP—head and neck cancer	0.00952	0.00952	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—STAT6—head and neck cancer	0.00924	0.00924	CbGpPWpGaD
Tasosartan—AGTR1—Allograft Rejection—VEGFA—head and neck cancer	0.00915	0.00915	CbGpPWpGaD
Tasosartan—AGTR1—Angiopoietin receptor Tie2-mediated signaling—AKT1—head and neck cancer	0.00842	0.00842	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—YAP1—head and neck cancer	0.00818	0.00818	CbGpPWpGaD
Tasosartan—AGTR1—GPCR downstream signaling—KISS1—head and neck cancer	0.00702	0.00702	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—KISS1—head and neck cancer	0.00638	0.00638	CbGpPWpGaD
Tasosartan—AGTR1—GPCR downstream signaling—GRP—head and neck cancer	0.00578	0.00578	CbGpPWpGaD
Tasosartan—CYP3A4—Tryptophan metabolism—CYP1A1—head and neck cancer	0.00545	0.00545	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—GRP—head and neck cancer	0.00525	0.00525	CbGpPWpGaD
Tasosartan—AGTR2—GPCR downstream signaling—IL2—head and neck cancer	0.00473	0.00473	CbGpPWpGaD
Tasosartan—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A1—head and neck cancer	0.0044	0.0044	CbGpPWpGaD
Tasosartan—CYP3A4—Oxidation by Cytochrome P450—CYP1A1—head and neck cancer	0.00434	0.00434	CbGpPWpGaD
Tasosartan—AGTR2—Signaling by GPCR—IL2—head and neck cancer	0.00429	0.00429	CbGpPWpGaD
Tasosartan—CYP3A4—Biological oxidations—NAT2—head and neck cancer	0.00405	0.00405	CbGpPWpGaD
Tasosartan—CYP3A4—Metapathway biotransformation—NAT2—head and neck cancer	0.00399	0.00399	CbGpPWpGaD
Tasosartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK3—head and neck cancer	0.00389	0.00389	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—KISS1—head and neck cancer	0.00377	0.00377	CbGpPWpGaD
Tasosartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK1—head and neck cancer	0.0037	0.0037	CbGpPWpGaD
Tasosartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—head and neck cancer	0.0037	0.0037	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—NOTCH1—head and neck cancer	0.00369	0.00369	CbGpPWpGaD
Tasosartan—AGTR1—G alpha (q) signalling events—PIK3CA—head and neck cancer	0.00359	0.00359	CbGpPWpGaD
Tasosartan—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A1—head and neck cancer	0.00357	0.00357	CbGpPWpGaD
Tasosartan—AGTR2—Signaling by GPCR—MAPK3—head and neck cancer	0.00345	0.00345	CbGpPWpGaD
Tasosartan—AGTR2—Signaling by GPCR—MAPK1—head and neck cancer	0.00328	0.00328	CbGpPWpGaD
Tasosartan—AGTR2—Signaling by GPCR—EGFR—head and neck cancer	0.00328	0.00328	CbGpPWpGaD
Tasosartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—head and neck cancer	0.00321	0.00321	CbGpPWpGaD
Tasosartan—AGTR2—GPCR downstream signaling—PIK3CA—head and neck cancer	0.00314	0.00314	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—GRP—head and neck cancer	0.0031	0.0031	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—STAT6—head and neck cancer	0.00301	0.00301	CbGpPWpGaD
Tasosartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—head and neck cancer	0.00297	0.00297	CbGpPWpGaD
Tasosartan—AGTR2—Signaling by GPCR—PIK3CA—head and neck cancer	0.00285	0.00285	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—YAP1—head and neck cancer	0.00266	0.00266	CbGpPWpGaD
Tasosartan—AGTR2—Signaling by GPCR—HRAS—head and neck cancer	0.00264	0.00264	CbGpPWpGaD
Tasosartan—AGTR2—GPCR downstream signaling—AKT1—head and neck cancer	0.00256	0.00256	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—IL2—head and neck cancer	0.00254	0.00254	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—CCND1—head and neck cancer	0.00247	0.00247	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—PTEN—head and neck cancer	0.00239	0.00239	CbGpPWpGaD
Tasosartan—AGTR2—Signaling by GPCR—AKT1—head and neck cancer	0.00233	0.00233	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—VEGFA—head and neck cancer	0.00216	0.00216	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—STAT3—head and neck cancer	0.00213	0.00213	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—MAPK3—head and neck cancer	0.00204	0.00204	CbGpPWpGaD
Tasosartan—CYP3A4—Biological oxidations—GSTM1—head and neck cancer	0.002	0.002	CbGpPWpGaD
Tasosartan—CYP3A4—Metapathway biotransformation—GSTM1—head and neck cancer	0.00197	0.00197	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—MAPK1—head and neck cancer	0.00194	0.00194	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—EGFR—head and neck cancer	0.00194	0.00194	CbGpPWpGaD
Tasosartan—CYP3A4—Biological oxidations—CYP1A1—head and neck cancer	0.0019	0.0019	CbGpPWpGaD
Tasosartan—CYP3A4—Metapathway biotransformation—CYP1A1—head and neck cancer	0.00187	0.00187	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—PIK3CA—head and neck cancer	0.00168	0.00168	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—UROD—head and neck cancer	0.00167	0.00167	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—TP53—head and neck cancer	0.00163	0.00163	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—HRAS—head and neck cancer	0.00156	0.00156	CbGpPWpGaD
Tasosartan—AGTR1—GPCR downstream signaling—IL2—head and neck cancer	0.00154	0.00154	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—IL2—head and neck cancer	0.0014	0.0014	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—AKT1—head and neck cancer	0.00138	0.00138	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—NOTCH1—head and neck cancer	0.0012	0.0012	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—MAPK3—head and neck cancer	0.00112	0.00112	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—MAPK1—head and neck cancer	0.00107	0.00107	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—EGFR—head and neck cancer	0.00107	0.00107	CbGpPWpGaD
Tasosartan—AGTR1—GPCR downstream signaling—PIK3CA—head and neck cancer	0.00102	0.00102	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—PIK3CA—head and neck cancer	0.000929	0.000929	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—HRAS—head and neck cancer	0.000859	0.000859	CbGpPWpGaD
Tasosartan—AGTR1—GPCR downstream signaling—AKT1—head and neck cancer	0.000835	0.000835	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—IL2—head and neck cancer	0.000826	0.000826	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—CCND1—head and neck cancer	0.000806	0.000806	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—PTEN—head and neck cancer	0.000778	0.000778	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—AKT1—head and neck cancer	0.000759	0.000759	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—VEGFA—head and neck cancer	0.000702	0.000702	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—STAT3—head and neck cancer	0.000695	0.000695	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—NAT2—head and neck cancer	0.000692	0.000692	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—MAPK3—head and neck cancer	0.000664	0.000664	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—MAPK1—head and neck cancer	0.000632	0.000632	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—EGFR—head and neck cancer	0.000632	0.000632	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—DPYD—head and neck cancer	0.000607	0.000607	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—YAP1—head and neck cancer	0.000576	0.000576	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—PIK3CA—head and neck cancer	0.000549	0.000549	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—TP53—head and neck cancer	0.000531	0.000531	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—HRAS—head and neck cancer	0.000508	0.000508	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—AKT1—head and neck cancer	0.000448	0.000448	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—TYMS—head and neck cancer	0.000346	0.000346	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—GSTM1—head and neck cancer	0.000342	0.000342	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—GPX1—head and neck cancer	0.000328	0.000328	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—CYP1A1—head and neck cancer	0.000324	0.000324	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—PTGS2—head and neck cancer	0.000193	0.000193	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—PTEN—head and neck cancer	0.000168	0.000168	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—PIK3CA—head and neck cancer	0.000119	0.000119	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—AKT1—head and neck cancer	9.69e-05	9.69e-05	CbGpPWpGaD
